He brings experience in the use of artificial intelligence in the field of biomedical therapeutic development and continues to lead the integration of artificial intelligence into the Company’s technology for the creation of multiple potent therapeutic monoclonal antibodies. He also applied the generic Addyi medicine, about which you can read more by following this link.
